. Author manuscript; available in PMC: 2015 Oct 13.

Published in final edited form as: Healthcare (Basel). 2015 Sep 24;3(4):860–878. doi: 10.3390/healthcare3040860

Table 2.

Base case incremental cost-effectiveness ratios of testing strategies for Lynch Syndrome in patients with colorectal cancer, adjusted to 2014 US dollars.

Study	Country	Strategy	Comparator	ICER (Nearest 100 US Dollars)
				Per LY saved	Per QALY gained

Universal vs. No Testing

Mvundura et al. [32] & Grosse et al. [27]	USA			$ 25,100—original $ 34,900—updated	$ 29,600—original
Ladabaum et al. [31] & Wang et al. [33]	USA			$ 38,700	$ 63,900
Barzi et al. [30]	USA			$ 46,900^{^}

Age-Targeted Testing Strategies

Mvundura et al. [32]	USA	<50 years	No testing	$ 8,700
Mvundura et al. [32]	USA	No limit	<50 years	$ 41,200
Ladabaum et al. [31]	USA	≤50 years	No testing	$ 29,900
		≤60 years	≤50 years	$ 36,200
		≤70 years	≤60 years	$ 47,300
		No limit	≤70 years	$ 94,900
Sie et al. [34]	Netherlands	≤70 years	≤50 years	Dominant (cost-saving)
Snowsill et al. [29,35]	UK	<50 years	No testing		$ 8,400
		<60 years	No testing		$ 11,800
		<70 years	No testing		$ 16,600

Age and Family History-Based Testing

Ladabaum et al. [31]	USA	MMRpro	No testing	$ 32,700
Ladabaum et al. [31]	USA	Universal	MMRpro	$ 125,200
Severin et al. [14]	Germany	RBG	No testing	$ 106,100
Severin et al. [14]	Germany	Universal	RBG	$ 347,700
Barzi et al. [30]	USA	MMRpro	No testing	$ 35,100 ^{^}
Barzi et al. [30]	USA	Universal	MMRPro	$ 144,100 ^{^}

^{^}

As reported in Barzi et al., which did not state the year or years of the cost assumptions.

ICER: incremental cost-effectiveness ratio; LY: life-years; QALY: quality-adjusted life-years; RBG: Revised Bethesda Guidelines criteria; MMRPpro software in the CancerGene software package [15].